OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Pusztai on the Role of ctDNA as a Biomarker in Breast Cancer

December 15th 2020

Lajos Pusztai, MD, DPhil, discusses the role of circulating tumor DNA as a biomarker of response in patients with high-risk early-stage breast cancer.

Dr. DeAngelo on the Mechanism of Action of Pevonedistat in MDS

December 15th 2020

Daniel J. DeAngelo, MD, PhD, discusses the mechanism of action of pevonedistat in myelodysplastic syndrome.

Dr. Brody on the Role of Immunotherapy in Hodgkin Lymphoma

December 14th 2020

Joshua Brody, MD, discusses the role of immunotherapy in Hodgkin lymphoma.

Dr. Weber on the Toxicities Associated With Immunotherapy in Lung Cancer

December 14th 2020

Jeffrey S. Weber, MD, PhD, discusses the toxicities associated with immunotherapy in lung cancer.

Dr. Agarwal on Remaining Challenges in mCSPC

December 11th 2020

Neeraj Agarwal, MD, remaining challenges in metastatic castration-sensitive prostate cancer.

Dr. Janjigian on the Emergence of New Treatment Options in Esophageal and Gastric Cancer

December 11th 2020

Yelena Y. Janjigian, MD, discusses the emergence of new treatment options in esophageal and gastric cancer.

Dr. Grothey on Investigational Combinations in MSI-High CRC

December 11th 2020

Axel Grothey, MD, discusses investigational combination therapies in microsatellite instability–high colorectal cancer.

Dr. Weber on Unmet Needs in Melanoma

December 9th 2020

Jeffrey S. Weber, MD, PhD, discusses unmet needs in melanoma.

Dr. Stadtmauer on the Evolving Treatment Landscape in Multiple Myeloma

December 9th 2020

Edward A. Stadtmauer, MD, discusses the evolving treatment landscape in multiple myeloma.

Dr. Spivak on Diagnosing Essential Thrombocythemia

December 9th 2020

Jerry Le Pow Spivak, MD, discusses diagnosing essential thrombocythemia.

Dr. Coffman on the Role of Targeted Therapy in TNBC

December 9th 2020

Lan G. Coffman, MD, PhD, discusses the role of targeted therapy in triple-negative breast cancer.

Dr. Pawlik on Advances in Management of mCRC With Liver Metastases

December 9th 2020

Timothy M. Pawlik, MD, PhD, MPH, discusses advances in the management of patients with metastatic colorectal cancer with liver metastases.

Dr. Rampal on the Evolution of Prognostic Models in Essential Thrombocythemia

December 8th 2020

Raajit K. Rampal, MD, PhD, discusses the evolution of prognostic models in essential thrombocythemia.

Dr. Tawbi on Future Research Efforts in Melanoma

December 8th 2020

Hussein A. Tawbi, MD, PhD, discusses future research efforts in melanoma.

Dr. Kahl on Remaining Challenges With CAR T-Cell Therapy in DLBCL

December 8th 2020

Brad S. Kahl, MD, discusses remaining challenges with CAR T-cell therapy in diffuse large B-cell lymphoma.

Dr. Matulonis on the Need to Improve Immunotherapy Responses in Gynecologic Cancers

December 8th 2020

Ursula A. Matulonis, MD, discusses the need to improve responses to immunotherapy among patients with recurrent gynecologic cancers.

Dr. Lin on Updated Results of the CRB-401 Trial in Relapsed/Refractory Multiple Myeloma

December 8th 2020

Yi Lin, MD, PhD, discussess updated results of the phase 1 CRB-401 study in relapsed/refractory multiple myeloma.

Dr. Zeiser on Results of the REACH3 Trial in Chronic GVHD

December 8th 2020

Robert Zeiser, MD, discusses results of the REACH3 trial in chronic graft-versus-host disease.

Dr. Hill on the Safety Profiles of BTK Inhibitors in MCL

December 7th 2020

Brian T. Hill, MD, PhD, discusses the safety profiles of BTK inhibitors in mantle cell lymphoma.

Dr. Schweizer on the Role of Olaparib in Non–BRCA-Mutant mCRPC

December 7th 2020

Michael Schweizer, MD, discusses the role of olaparib in patients with non–BRCA-mutant metastatic castration-resistant prostate cancer.